Literature DB >> 24793939

Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China.

Wenyu Kang1, Zhengrong Ding1, Liping Shen2, Zhixian Zhao1, Guofei Huang1, Jie Zhang1, Qing Xiong1, Shuang Zhang3, Shuo Zhang3, Feng Wang3.   

Abstract

OBJECTIVE: To explore the risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus (HBV) and hepatitis B vaccination status in Yunnan province, China.
METHODS: Multicenter cluster sampling was used to select pregnant women who were positive for hepatitis B surface antigen (HBsAg). HBV immunoprophylaxis was carried out for the newborns. Blood samples were collected and tested for HBV markers from 7 to 10 month old infants. The factors were analyzed by univariate and logistic regression.
RESULTS: A total of 2765 mothers and their infants were enrolled. The failure rate of prevention of mother to child transmission (PMTCT) was 4.12%. The rate of timely HepB1 vaccination within 24h was 98.04%, the rate of three-dose vaccination was 92.30% and the rate of hepatitis B immune globulin (HBIG) administration was 68.97%. Place of residence, maternal education, gestational age and birth weight were related to administration of HBV immunoprophylaxis. It was remarkable that the rate of HBIG administration of infants was only 63.89% with whose mothers were both HBsAg and hepatitis B e antigen (HBeAg)-positive. Further analysis showed that there were three risk factors associated with HBV immunoprophylaxis failure: mothers who were positive for HBsAg and HBeAg, maternal HBVDNA level, and HBIG administration or not.
CONCLUSIONS: PMTCT of HBV was well implemented in Yunnan. However, in order to achieve optimal prevention of vertical HBV transmission, it is mandatory to make additional efforts to improve the implementation of regulatory HBV immunoprophylaxis, especially for HBsAg-positive pregnant women.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus; Immunoprophylaxis; Mother-to-child transmission; Risk factor

Mesh:

Substances:

Year:  2014        PMID: 24793939     DOI: 10.1016/j.vaccine.2014.04.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

2.  Occult hepatitis B virus infection in children born to HBsAg-positive mothers after neonatal passive-active immunoprophylaxis.

Authors:  Hanan Foaud; Sahar Maklad; Faten Mahmoud; Hanaa El-Karaksy
Journal:  Infection       Date:  2015-02-10       Impact factor: 3.553

Review 3.  Viral hepatitis and pregnancy.

Authors:  Norah A Terrault; Miriam T Levy; Ka Wang Cheung; Gonzague Jourdain
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-12       Impact factor: 46.802

4.  The effectiveness of 20 μg hepatitis B vaccine used for the prevention of HBV vertical transmission.

Authors:  Guo Yonghao; Chen Yanping; Dou Qiaohua; Feng Daxing; Zhang Yanyang; Zhao Dongyang; Guo Wanshen
Journal:  Sci Rep       Date:  2022-07-11       Impact factor: 4.996

5.  Long-term effectiveness of plasma-derived hepatitis B vaccine 22-28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed?

Authors:  H Li; G J Li; Q Y Chen; Z L Fang; X Y Wang; C Tan; Q L Yang; F Z Wang; F Wang; S Zhang; S L Bi; L P Shen
Journal:  Epidemiol Infect       Date:  2017-01-09       Impact factor: 4.434

6.  Investigation of a Novel Hepatitis B Virus Surface Antigen (HBsAg) Escape Mutant Affecting Immunogenicity.

Authors:  Md Golzar Hossain; Keiji Ueda
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

7.  Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China.

Authors:  Fuqiang Cui; Lipin Shen; Li Li; Huaqing Wang; Fuzhen Wang; Shengli Bi; Jianhua Liu; Guomin Zhang; Feng Wang; Hui Zheng; Xiaojin Sun; Ning Miao; Zundong Yin; Zijian Feng; Xiaofeng Liang; Yu Wang
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

8.  Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure.

Authors:  Chong Wang; Chuan Wang; Zhi-Fang Jia; Xing Wu; Si-Min Wen; Fei Kong; Ke-Qin Hu; Jie Li; Jing Jiang; Jun-Qi Niu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 9.  Host Genetic Determinants of Hepatitis B Virus Infection.

Authors:  Zhenhua Zhang; Changtai Wang; Zhongping Liu; Guizhou Zou; Jun Li; Mengji Lu
Journal:  Front Genet       Date:  2019-08-13       Impact factor: 4.599

10.  Hepatitis B vaccine adverse events in China: risk control and regulation.

Authors:  Li Meina; Liu Xiaodong; Zhang Lulu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.